Alefacept

CHEMBL1201571 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A biologic medication that targets and reduces the number of activated T cells that drive the abnormal immune response responsible for psoriasis. It works by blocking CD2 on T cells and promoting their destruction, thereby reducing the immune-mediated inflammation that causes the thickened, scaly skin plaques characteristic of psoriasis.

Area Terapeutik

Psoriasis Lymphoma Atopic Dermatitis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A biologic medication that targets and reduces the number of activated T cells that drive the abnormal immune response responsible for psoriasis. It works by blocking CD2 on T cells and promoting their destruction, thereby reducing the immune-mediated inflammation that causes the thickened, scaly skin plaques characteristic of psoriasis.

Yes, Alefacept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201571. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Alefacept di PillFYI

Data Cepat

Tautan Eksternal

ChEMBL CHEMBL1201571

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.